Description

Argatroban is a synthetic direct thrombin inhibitor widely used in research for heparin-induced thrombocytopenia, thrombosis prevention, and acute ischemic stroke models. It binds reversibly to thrombin’s active site, inhibiting clot formation without affecting platelets directly.

Each vial contains 10?mg in 20?ml sterile solution—clear and colorless. Manufactured by Hunan Sailong Pharmaceutical Co., Ltd., it is NMPA-approved under H20193374 and H20227090, with barcode 6973398250101

?? For laboratory research use only. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Argatroban directly inhibits thrombin (factor IIa), blocking fibrin formation and thrombus development. It is frequently utilized in lab studies of:

• Heparin-induced thrombocytopenia (HIT)

• Acute ischemic stroke interventions

• Venous thromboembolism prevention

• Pharmacodynamics and coagulation assays

Vials are ready for dilution and IV use in controlled experimental settings.

Side Effects (Observed in Preclinical Use)

At high research doses, argatroban may induce:

• Bleeding or hemorrhage risk, including gastrointestinal or intracranial bleeding

• Hypotension due to anticoagulation

• Local reaction at injection site in animal models

Monitor coagulation parameters consistently during use.

Safety & Handling

Use in a controlled research environment only. Requires PPE: gloves, lab coat, goggles. Dispose according to biohazard and chemical waste regulations. Stored at ambient temperature and protected from light.

Research Use Disclaimer

This product is intended solely for laboratory research. It is not approved for therapeutic, diagnostic, or veterinary use. Misuse may cause serious legal and health consequences. Always adhere to institutional and regulatory protocols.